Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

ClinicalTrials.gov ID: NCT04620733

Public ClinicalTrials.gov record NCT04620733. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purposes of this study are to evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo. The study also checked the effect of treatment on the symptoms of PBC, including pruritus.

Study identification

NCT ID
NCT04620733
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
193 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 20, 2021
Primary completion
Aug 10, 2023
Completion
Aug 10, 2023
Last update posted
Sep 4, 2024

2021 – 2023

United States locations

U.S. sites
40
U.S. states
21
U.S. cities
34
Facility City State ZIP Site status
The Institute for Liver Health DBA Arizona Liver Health Chandler Arizona 85224
Arkansas Diagnostic Center Little Rock Arkansas 72205
Stanford University School of Medicine Palo Alto California 94305
California Liver Research Institute Pasadena California 91105
University of California, Davis Medical Center Sacramento California 95817
California Pacific Medical Center - Sutter Pacific Medical Foundation San Francisco California 94109
Covenant Metabolic Specialists, LLC Fort Myers Florida 33912
Florida Research Institute Lakewood Rch Florida 34211
Schiff Center for Liver Diseases/University of Miami Miami Florida 33136
Covenant Research and Clinics, LLC Sarasota Florida 34240
Digestive Healthcare of Georgia Atlanta Georgia 30309
Rush University Medical Center Chicago Illinois 60612
University of Chicago Hospitals Chicago Illinois 60637
Tulane University Health Sciences Center New Orleans Louisiana 70112
Mercy Medical Center Baltimore Maryland 21202
Massachusetts General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Henry Ford Health System Novi Michigan 48377
MNGI Digestive Health, P.A. Maplewood Minnesota 55117
Southern Therapy and Advanced Research, LLC (STAR) Jackson Mississippi 39216
Saint Louis University St Louis Missouri 63104
NYU Langone Health / NYU Grossman School of Medicine New York New York 10016
Weill Cornell Medical College New York New York 10021
Icahn School of Medicine at Mount Sinai New York New York 10029
University of Rochester Medical Center Rochester New York 14642
Care Access Research - Lumberton Lumberton North Carolina 28358
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Penn State Milton S Hershey Medical Center Hershey Pennsylvania 17033
UPMC Center for Liver Diseases Pittsburgh Pennsylvania 15213
Galen Hepatology Chattanooga Tennessee 37421
Gastro One Germantown Tennessee 38138
Vanderbilt Digestive Disease Center Nashville Tennessee 37212
The Liver Institute at Methodist Dallas Medical Center Dallas Texas 75203
University of Texas Southwestern Medical Center Dallas Texas 75390
Texas Digestive Disease Consultants dba GI Alliance Fort Hood Texas 76104
Baylor College of Medicine Houston Texas 77030
American Research Corporation at the Texas Liver Institute San Antonio Texas 78215
Pinnacle Clinical Research, PLLC San Antonio Texas 78229
Bon Secours Richmond Community Hospital LLC Richmond Virginia 23226
Liver Institute Northwest Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04620733, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 4, 2024 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04620733 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →